{"abstract":"The National Human Genome Research Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Leadiant Biosciences, Inc, located in Gaithersburg, Maryland, USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/12/08/2017-26540.html","cfr_references":[],"citation":"82 FR 58007","comment_url":null,"comments_close_on":"2017-12-26","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before December 26, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-26540","effective_on":null,"end_page":58008,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/12/08/2017-26540.xml","html_url":"https://www.federalregister.gov/documents/2017/12/08/2017-26540/prospective-grant-of-exclusive-patent-license-n-acetyl-mannosamine-as-a-therapeutic-agent","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-26540?publication_date=2017-12-08","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-12-08/2017-26540/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":143,"last_updated":"2026-04-04 20:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-12-08/pdf/2017-26540.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-26540.pdf?1512654378","publication_date":"2017-12-08","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/12/08/2017-26540.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T20:13:39Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":58007,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: N-Acetyl Mannosamine as a Therapeutic Agent","toc_doc":"N-Acetyl Mannosamine as a Therapeutic Agent","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}